Researchers plan brain scans on about 180 people to see if GLP-1 use changes the reward system behind choices about food and money.
Recap by typeshit. Full story at WTVR.com.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
The study will scan the brains of about 180 people as they make food and money choices, looking for changes in how the reward system handles instant gratification.
Hoyos says second and third generation GLP-1s could reshape obesity care, while asking whether they'll prove more effective with fewer side effects.
Loading…